Jpmorgan Chase & CO Neuronetics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Neuronetics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 4,212 shares of STIM stock, worth $4,591. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,212
Previous 34
12288.24%
Holding current value
$4,591
Previous $0
Infinity%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding STIM
# of Institutions
69Shares Held
18.3MCall Options Held
0Put Options Held
3.8K-
Archon Capital Management LLC Seattle, WA2.47MShares$2.7 Million3.67% of portfolio
-
Cannell Capital LLC Alta, WY2.38MShares$2.6 Million1.07% of portfolio
-
Kent Lake Capital LLC Mill Valley, CA1.74MShares$1.89 Million1.44% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.3MShares$1.42 Million0.0% of portfolio
-
First Washington Corp Seattle, WA1.27MShares$1.39 Million0.89% of portfolio
About Neuronetics, Inc.
- Ticker STIM
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 27,022,800
- Market Cap $29.5M
- Description
- Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive diso...